Mach7 Wins Long-Term Deal with US Teleradiology Provider
Mach7 Technologies Limited (ASX: M7T) has secured a new five-year agreement with American Radiologist Network Inc. (AMRADNET), a growing teleradiology company in the United States. The partnership involves the use of Mach7’s eUnity Viewer platform to support remote diagnostic imaging services across healthcare facilities.
The agreement carries an initial contract value of approximately AU$1.7 million and is based on annual imaging volumes of at least 675,000 studies. The company also expects scan volumes to increase beyond one million studies during the contract period as AMRADNET expands its operations into additional healthcare segments, including cardiology, neurology, and telemedicine.
Mach7 highlighted that the expected deployment timeframe has been significantly reduced, with first productive use anticipated within 45 days instead of the usual year-long implementation cycle. The company believes this reflects recent operational improvements and stronger execution capabilities, while also strengthening its presence in the rapidly growing healthcare imaging technology market.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Mach7 Wins Long-Term Deal with US Teleradiology Provider
Mach7 Technologies Limited (ASX: M7T) has secured a new five-year agreement with American Radiologist Network Inc. (AMRADNET), a growing teleradiology company in the United States. The partnership involves the use of Mach7’s eUnity Viewer platform to support remote diagnostic imaging services across healthcare facilities.
The agreement carries an initial contract value of approximately AU$1.7 million and is based on annual imaging volumes of at least 675,000 studies. The company also expects scan volumes to increase beyond one million studies during the contract period as AMRADNET expands its operations into additional healthcare segments, including cardiology, neurology, and telemedicine.
Mach7 highlighted that the expected deployment timeframe has been significantly reduced, with first productive use anticipated within 45 days instead of the usual year-long implementation cycle. The company believes this reflects recent operational improvements and stronger execution capabilities, while also strengthening its presence in the rapidly growing healthcare imaging technology market.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au